Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).

@article{Gregory2001MitomycinCV,
  title={Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).},
  author={R. Kate Gregory and Ian E. Smith and Alison Norton and Susan W. Ashley and Mary R O'Brien},
  journal={Clinical oncology (Royal College of Radiologists (Great Britain))},
  year={2001},
  volume={13 6},
  pages={483-7}
}
The majority of patients diagnosed with non-small cell lung carcinoma (NSCLC) present with advanced disease and, as such, are treated with palliative intent. Platinum-based combination chemotherapy plays an important role in the management of these patients, with response rates to most regimens being in the range of 30%-40%. with symptom relief in up to 60%. One of the most commonly utilized combinations is mitomycin C, vinblastine and cisplatin (MVP). Owing to the hydration regimen, and to the… CONTINUE READING